AzTrials
AzTrials

PrematurityNCT04723654

Evaluating Wearable Smart Sensors for Continuous Measurement of Vital Signs in ICU Patients

An observational study of Prematurity, run by Ann & Robert H Lurie Children's Hospital of Chicago at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to develop biocompatible wireless electronic devices that will allow continuous, non-invasive hemodynamic and physiology measurements in the ICU. Read more about this study

Who is it for?
Ages Up to 18 yearsHealthy volunteers can take part
Conditions the study is for
Prematurity
What is being tested?
Wireless Wearable Vital Sign Monitor
Type of treatment
Medical device
How many people
500 participants
Where
2 sitesUnited States
Study dates
15 Mar 2018to 30 Nov 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: Patients admitted to one of 3 ICUs at Lurie Children's, or healthy volunteers visiting CAMP at Lurie Children's

Who may be able to join

  • Admitted to one of the four ICUs at Lurie Children's or Prentice Women's Hospital
  • Under 18 years of age
  • Under 18 years of age
  • Willing to visit the Center for Autonomic Medicine in Pediatrics (CAMP) for a one time study visit

Who cannot join

  • A skin abnormality that would potentially increase the risk of device
  • 18 years of age or older
  • Determined by an attending physician or bedside care team to be too unstable (patient) or experiencing too much stress (family)
  • A skin abnormality that would potentially increase risk of device use
  • 18 years of age or older

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States2 sites, 2 recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611

    Susan Slattery, MD, 312-227-3300, sslattery@luriechildrens.org

    Recruiting
  • Northwestern Medicine Prentice Women's Hospital

    Chicago, Illinois, 60611

    Susan Slattery, MD, 312-227-3300, sslattery@luriechildrens.org

    Recruiting

Other trials in United States

About this study

Official title: Evaluating Wearable Smart Sensors for Continuous Measurement of Vital Signs in ICU

The purpose of this study is to develop biocompatible wireless electronic devices that will allow continuous, non-invasive hemodynamic and physiology measurements in the ICU.

Read the detailed description

Screening: All ICU patients will be screened by the study team based on inclusion and exclusion criteria through review of electronic medical records. For screening at Prentice Women's Hospital, screening criteria will be automatically applied through the use of the electronic data warehouse, and information from infants meeting this screening criteria will be transferred to the study team through electronic data warehouse. A screening and enrollment log will be kept to track ICU patients/parents who have been approached and agreed or declined to participate in the study. The screening and enrollment log will be kept on the Northwestern University housed REDCap server. Only the study team will have access to this log. All non-ICU participants will be screened through question and answer with a parent or guardian.

Device application: Standard devices will be used continuously in all subjects and this data compared to that collected using novel wearable sensors suggested in this study. In the ICU population, after patients are consented in the ICU, multiple wearable sensors (up to 5) will be placed on the patient for the duration of the study. Multiple devices are required to estimate BP. One or more devices will be placed on the chest or back, and one or more additional devices will be placed peripherally (e.g. leg, foot, arm, hand, head, or ear). Placing multiple devices will allow determination of which location provides the best signals in specific ICU populations. These devices will be placed using a medical grade skin adhesive similar to the ones used in the ICUs, which will minimize the risk of skin irritation or allergic reaction. Alternatively, the investigators are currently testing a "soft wrap-around device" (similar to that currently used for blood pressure monitoring in the premature babies) with a sensor. The soft wrap-around device is composed of hypoallergenic cotton. Overlying this cotton, and not touching the subject's skin, may include Coban wraps, paper tape, or a Velcro adhesion mechanism. Given the very small size of premature infants in the NICU, the investigators may incorporate this new technology as needed in the NICU. Each device is encapsulated in medical grade materials and applied using medical grade adhesive. The adhesives will be changed between uses. The device itself will be re-used. It will be cleaned with Super Sani-Cloth between each use. In the ICU population, devices will be left in place for up to 48 hours, but will be checked by study staff to ensure skin integrity and signal quality at least once every 24 hours. In the non-ICU population, standard of care devices will be attached to participants according to ICU standard of care procedures. The wearable sensors will be placed in the same manner as outlined above but will be left in place for only up to 3 hours during an outpatient study visit to the Center for autonomic Medicine in Pediatrics (CAMP).

The investigators have recently upgraded a new firmware version activating the ability for the sensor to continuously measure bioimpedance for respiratory rate. This function does not require any modification to the physical device itself or the adhesive. However, the bioimpedance functionality does require delivery of low amplitude sinusoidal current through the electrodes of the chest unit. The frequency of the current is 4 kHz - a frequency range used typically for human bioimpedance measurements by FDA cleared systems. The maximum current delivered is 8 μA. These parameters are below commonly used body fat percentage impedance analyzers that are widely commercially available. Furthermore, bioimpedance is standardly used in NICUs / PICUs leveraging the ECG electrodes that are then displayed on standard of care monitors. Commercially bioimpedance devices that are FDA approved inject currents that are 10x greater than our system (e.g. the CoVa Monitoring System 2 for continuous wearable sensing of thoracic impedance). Finally, the parameters in our sensor follow IEC 60601-1-2 guidelines for electromagnetic safety.

Video monitoring: In some participants, video monitoring of participant position and movement will be utilized during the study. This is an optional, additional part of the study in which families can choose to participate or not participate. If a family chooses to participate, a video camera will be utilized to capture participant movement and position for the duration of the study in the ICU or at CAMP.

Cuff-based blood pressure: While the wearable sensors are attached to participants in both the ICU and non-ICU populations, the participants will also be monitored with the normal standard of care monitoring montage. In addition, during one 3- or 4-hour period while the wearable sensors are attached to the patient, a member of the study team may take the participant's BP using the ICU standard cuff-based method every 15 minutes. Cuff-based measures typically happen every 15-60 minutes for standard clinical care, depending on the stability of the patient and physician discretion. In the ICU cohort, if a standard clinical cuff-based BP measure is taken during the 15-minute time epoch, the clinical measurements will be used rather than obtaining a separate research measurement. Outside of this 3- or 4-hour window and for the remainder of the study duration in the ICU population, cuff-based BP measures will be made only as frequently as needed for standard clinical care.

Skin temperature: While the wearable sensors are attached to the participant, skin temperatures will be taken using a standard infrared thermometer. These measurements will be made at the same interval as the above cuff-based BP, over the same 3- or 4-hour period by a member of the study team. Outside of this 3- or 4-hour window, no skin temperature measures will be made for research purposes.

Device data: Wearable sensors can stream data continuously using near field communication (NFC) or Bluetooth technology. An encrypted laptop, iPad, or similar device will be left in the patient or CAMP study room and used to capture the continuous data stream from the wearable sensor. Additionally, wearable sensors can include onboard memory, and physiologic streams may be recorded to this onboard memory until transfer to an encrypted laptop for analysis.

Standard of care data: In all participants where data from standard of care monitoring is captured and stored using the BedMasterEx system (all PICU and CCU beds, some NICU beds), these data will be used for comparison to data captured using EWP. In any participants where data are not captured and stored using the BedMasterEx system, video recordings will be made of the Phillips monitors using an encrypted mobile device. Within 48 hours, videos will be downloaded and transferred to a HIPAA secure server. In NICU patient without BedMasterEx data, the Somnostar system may be used to capture data for up to 4 hours of the study. All study data will be stored on an encrypted laptop and/or secure networkfor analysis.

Skin integrity: Before and after wearable sensors are placed on the participant, the participant's skin integrity will be monitored using the ICU standard protocol, either the Braden Q scale (≥6 months of age) and/or Neonatal Skin Risk Assessment Scale (NSRAS; <6 months of age). Additionally, a member of the study team will use a validated skin integrity scale to score participants' skin condition at sensor placement site before sensor placement and immediately after sensor removal. At both of these time points, photographs will be taken of the participants' skin at the site of sensor placement to document any skin changes that occur during the period of wearable sensor wear. No faces will be photographed. Additional skin scores and photographs may be performed/taken between 30 minutes and 24 hours after sensor removal, as deemed necessary by the study and/or clinical team. The study team will consult the ICU bedside care team or CAMP clinical team within 1 hour for any concerning changes in skin integrity.

Questionnaires: After the study period ends, the parents will be approached to complete the questionnaires. These questionnaires will take less than 10 minutes to complete and are meant to assess opinions on use of these devices in the ICUs. These questionnaires will be completed using REDCap or a printed version of the REDCap questionnaire. All questionnaire data will be stored on the secure REDCap server housed by Northwestern University.

Conditions
Prematurity
Being tested
Wireless Wearable Vital Sign Monitor
Keywords
Blood Pressure, Vital Signs, Wireless Monitoring
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Wireless Wearable Vital Sign MonitorDevice

    Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours

Study groups in NCT04723654
Study groupRoleWhat they receive
ICU PopulationPatients admitted to one of 3 ICUs at Lurie Childrens
Receives: Device: Wireless Wearable Vital Sign Monitor
Non-ICU PopulationHealthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
Receives: Device: Wireless Wearable Vital Sign Monitor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Continuous non-invasive BP monitoring

    Recorded measurements of BP as compared to the ICU standard of care monitoring, including both arterial line measurements and cuff-based measurements of the arm (mm Hg).

    Measured: up to 48 hours

Secondary outcomes (1)
  1. Accuracy of Other Physiologic Signals

    correlation of vital signs to current technology used on the units: heart rate (beats/min); respiratory rate (breaths/min); temperature (degrees Celsius); oxygen saturation (SpO2, %)

    Measured: up to 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jan 2021
  2. Study start15 Mar 2018
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion30 Nov 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04723654
Sponsor's protocol ID
2018-1668
Status last verified
Jun 2026
First submitted
13 Jan 2021
Last updated
17 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Chung HU, Rwei AY, Hourlier-Fargette A, Xu S, Lee K, Dunne EC, Xie Z, Liu C, Carlini A, Kim DH, Ryu D, Kulikova E, Cao J, Odland IC, Fields KB, Hopkins B, Banks A, Ogle C, Grande D, Park JB, Kim J, Irie M, Jang H, Lee J, Park Y, Kim J, Jo HH, Hahm H, Avila R, Xu Y, Namkoong M, Kwak JW, Suen E, Paulus MA, Kim RJ, Parsons BV, Human KA, Kim SS, Patel M, Reuther W, Kim HS, Lee SH, Leedle JD, Yun Y, Rigali S, Son T, Jung I, Arafa H, Soundararajan VR, Ollech A, Shukla A, Bradley A, Schau M, Rand CM, Marsillio LE, Harris ZL, Huang Y, Hamvas A, Paller AS, Weese-Mayer DE, Lee JY, Rogers JA. Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units. Nat Med. 2020 Mar;26(3):418-429. doi: 10.1038/s41591-020-0792-9. Epub 2020 Mar 11.

    PubMed 32161411
  • Chung HU, Kim BH, Lee JY, Lee J, Xie Z, Ibler EM, Lee K, Banks A, Jeong JY, Kim J, Ogle C, Grande D, Yu Y, Jang H, Assem P, Ryu D, Kwak JW, Namkoong M, Park JB, Lee Y, Kim DH, Ryu A, Jeong J, You K, Ji B, Liu Z, Huo Q, Feng X, Deng Y, Xu Y, Jang KI, Kim J, Zhang Y, Ghaffari R, Rand CM, Schau M, Hamvas A, Weese-Mayer DE, Huang Y, Lee SM, Lee CH, Shanbhag NR, Paller AS, Xu S, Rogers JA. Binodal, wireless epidermal electronic systems with in-sensor analytics for neonatal intensive care. Science. 2019 Mar 1;363(6430):eaau0780. doi: 10.1126/science.aau0780.

    PubMed 30819934

Questions about this trial

What is this clinical trial studying?

An observational study of Prematurity, run by Ann & Robert H Lurie Children's Hospital of Chicago at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Susan Slattery, MD (312-227-3300, sslattery@luriechildrens.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Continuous non-invasive BP monitoring (time frame: up to 48 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04723654, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in